Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

STEP 3 Uworld > IM endo medications > Flashcards

IM endo medications Flashcards

1
Q

Major drug interactions of levothyroxine - decreased absorption

A
  1. bile acid binding agents
  2. iron, calcium, alum hydroxide
  3. PP, sucralfate
    always 30-60 hour before brekfast (4 hours seperated from iron)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Major drug interactions of levothyroxine - increased TBG

A
  1. Estrogens

2. Tamoxifen

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Major drug interactions of levothyroxine - decreased TBG

A
  1. androgens

2. steroids

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Major drug interactions of levothyroxine - increased metabolism

A
  1. rifampin
  2. phenytoin
  3. carbamazepine
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

insulin preparations - rapid-acting - drugs? peak and duration

A
  1. aspart
  2. Lispro
  3. Glulisine
    1-3h / 4-6h
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

insulin preparations - short acting - drugs?peak and duration

A

regular

1.4-3.5 / 8

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

insulin preparations - intermediate acting - drugs? peak and duration

A

NPH

4-6 / 12

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

insulin preparations - long acting - drugs? peak and duration

A

detemir 3-9/6-24
glargine none / 24
Degludec none / more than 24

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

regular insulin charachteristics: regular vs short acting

A

regular peak does not coincident with food peak

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

long - acting - which does not cause hypoglycemia

A

the peakless (glargine and degludec)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

5 steps of management of hyperglycemia + DM in inpatients

A
  1. classify type (1 vs 2 vs stressed induced hypergl)
  2. determine dietary status
  3. determine preadmission glycemic control
  4. stop all oral drugs
  5. determine insulin regimen
    MAINTAIN 140-180
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

5 steps of management of hyperglycemia + DM in inpatients - step 5 (insulin regimen) options

A
  1. Basal bolus regimen
  2. Insulin sliding scale only
  3. insulin infusion
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Basal bolus regimen - who

A
  1. DM1
  2. DM2 treated with basal before admission
  3. DM3 inadequately controlled with sliding scale
  4. New diafgnosed or high gl
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Insulin sliding scale only - who

A

DM2 well control with diet or oral medication before admission
- addition of basal if suboptimal with sliding

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

insulin infusion - who

A
  1. hypergl emergencies
  2. DM1 perioperative or during labor
  3. DM1 who do not eating + glucose suboptimal with SC
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Insulin sliding scale?

A

varies the dose of insulin based on blood glucose level.

17
Q

metoformin - side effects

A
  1. GI upset

2. lactic acidosis (in renal failure)

18
Q

sulfonylureas - drugs?

A

first generation: chlorpropamide, tolbutamine

seond generation: glimepiride, glipizide, glypuride

19
Q

sulfonylureas toxicities

A
  1. increased risk of hypoglycemia in renal failure
  2. first generation: disulfiram like reaction
  3. second generation: hypoglycemia
  4. Weight gain
20
Q

Glitazone/thiazolidinediones - drugs

A
  1. pioglitazone

2. rosiglitazone

21
Q

Glitazone/thiazolidinediones - toxicity

A
  1. weight gain
  2. edema
  3. hepatotoxicity
  4. Heart failure
  5. increased risk for FRUCTURES
22
Q

GLP-1 analogs - drugs

A
  1. exenatide

2. Liraglutide

23
Q

GLP-1 analogs - toxicities

A
  1. nausea
  2. vomiting
  3. pancreatitis
  4. modest weight loss
24
Q

DDP-4 inhibitors - drugs

A
  • GLIPTIN
    1. Linagliptin
    2. Saxagliptin
    3. Sitagliptin
25
Q

DDP-4 inhibitors - toxicities

A

Mild urinary or respiratory infections

wight neutral

26
Q

SGLT-2 inhibitors - drugs

A
  • GLIFLOZIN

1. Canagliflozin 2. dapagliflozin 3. empagliflozin

27
Q

SGLT-2 inhibitors - side effects

A
  1. Glucosuria
  2. UTIs
  3. vaginal yeast infection
  4. hyperkalemia
  5. dehydration (orthostatic hypertension)
  6. EUGLYCEMIC DKA
28
Q

α-glcosidase inhibitors - drugs

A
  1. acarbose

2. Miglitol

29
Q

Meglitinides - drugs

A
  • Glinide
    1. Nateglinide
    2. Repaglinide
30
Q

Meglitinides - side effects

A
  1. weight gain

2. increased risk for hypoglycemia in renal failure

31
Q

treatment of severe hypoglycemia

A

IM glucagon in nonmedical setting (if glucagon is not available –> buccal or sublingual glucose
IV dextrose in medical setting
if mild hypoglycemia –>oral glucose (eg. juice)

32
Q

thyroid effects of amiodarone (and treatment)

A
  1. Decreased T4-3 conversion (none)
  2. inhibition of synthesis (levo)
  3. iodine induced increased of hormones (antithyr)
  4. destructive thyroiditis (steroids)
33
Q

primary ovarian insuf - treatment

A

estrogen + progestin

34
Q

Anti-thyroid meds during pregn

A

PTU in 1st trimester

Methimazol in 2nd and 3rd

35
Q

treatment of chronic hypoparathyroidism

A
  1. Vitamin D (over calcitriol the active form because cheaper)
  2. Ca2+
  3. thiazide (if low serum and high urine
36
Q

ADH antagonists

A

conivaptan, tolvaptan

37
Q

Cinacalcet

A

sensitizes CA2+ SENSING RECEPTORS

for 1ry and 2ry hyperparath

STEP 3 Uworld (14 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions